Query author contributions in Reactome
Reactome depends on collaboration between our curation team and outside experts to assemble and peer-review its pathway modules. The integration of ORCID within Reactome enables us to meet a key challenge with authoring, curating and reviewing biological information by incentivizing and crediting the external experts that contribute their expertise and time to the Reactome curation process. More information is available at ORCID and Reactome.
If you have an ORCID ID that is not listed on this page, please forward this information to us and we will update your Reactome pathway records.
Details on Person Aberrant signaling by activated forms of ALK can be inhibite...
| Class:Id | Summation:9700657 |
|---|---|
| _displayName | Aberrant signaling by activated forms of ALK can be inhibite... |
| _timestamp | 2023-10-14 19:29:09 |
| created | [InstanceEdit:9700663] Rothfels, Karen, 2020-09-16 |
| modified | [InstanceEdit:9717339] Rothfels, Karen, 2021-03-08 [InstanceEdit:9851215] Rothfels, Karen, 2023-10-14 |
| text | Aberrant signaling by activated forms of ALK can be inhibited by tyrosine kinase inhibitors (TKIs). ALK, like other tyrosine kinase receptors, is activated through a series of phosphorylation and conformational changes that move the receptor from the inactive form to the fully activated form. Type II TKIs bind to the inactive form of the receptor at a site adjacent to the ATP-binding cleft, while type I TKIs bind to the active form (reviewed in Roskoski, 2013). Type I inhibitors crizotinib, brigatinib, alectinib, ceritinib and lorlatinib are all approved for treatment of ALK-dependent cancer. Development of resistance to TKIs is not uncommon, however, either through acquisition of secondary mutations or through activation of bypass pathways that remove the dependence on ALK signaling (reviewed in Lovly and Pao, 2012; Lin et al, 2017; Della Corte et al, 2018). |
| (summation) | [Pathway:9700645] ALK mutants bind TKIs [Homo sapiens] |
| [Change default viewing format] | |
No pathways have been reviewed or authored by Aberrant signaling by activated forms of ALK can be inhibite... (9700657)
